MPH, School of Public Health
Boston University, Boston, MA
Louis Lowy Certificate of Studies in Gerontology
Summer Program on Health Care in Developing Countries, Center for International Health
Boston University School of Public Health, Boston, MA
Specialist in Preventive Medicine and Public Health
Hospital Clinic i Provincial de Barcelona and Ministry of Health, Barcelona, Spain
MD, Medicine
University of Barcelona, Barcelona, Spain
Elena Rivero has 26 years of experience in the pharmacoepidemiology field, specifically in an international pharmaceutical setting. At RTI HS, Dr. Rivero provides epidemiology expertise to a wide range of development projects and marketed products in various therapeutic areas, including transplantation, immunology, dermatology, gastroenterology, ophthalmology, and bone disease. She leads studies aimed at defining burden of disease, disease risk factors, and safety; supports sections of regulatory submissions and risk-management plans; and coordinates and leads postauthorization safety studies, including large database studies. She also coordinates epidemiology activities to prepare regulatory documents on benefit-risk review for various marketed products, including the preparation of Food and Drug Administration advisory committees and European Medicines Agency oral hearings. Dr. Rivero was a member of the steering committee of the IMI PROTECT project, for which she was also a contributing member of the WP2 on framework for pharmacoepidemiology studies and co-led the WP7 on training and communication. Prior to her work in the pharmaceutical industry, Dr. Rivero held a position as a clinical epidemiologist at the Consorci Hospitalari Parc Tauli in Sabadell, Spain, where she led various projects on the development of an integrated hospital information system and contributed to the setup of the Spanish Cochrane Collaboration Center. Dr. Rivero is a fellow and active member of the International Society for Pharmacoepidemiology, where she also previously served on the Board of Directors and the Special Interest Group of Medications in Pregnancy.